July 20 (Reuters) - GlaxoSmithKline Plc:
* GSK AND CUREVAC ENTER COLLABORATION
* GSK TO MAKE EQUITY INVESTMENT OF £130M (EUR 150M) IN CUREVAC, AND AN UPFRONT PAYMENT OF £104M (EUR 120M)
* COMPANIES TO COLLABORATE ON MRNA VACCINE AND MONOCLONAL ANTIBODY RESEARCH PROGRAMMES IN INFECTIOUS DISEASES
* CUREVAC WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS OF UP TO £277M (EUR 320M)
* COMPANIES TO COLLABORATE ON MRNA VACCINE AND MONOCLONAL ANTIBODY RESEARCH PROGRAMMES IN INFECTIOUS DISEASES
* CUREVAC WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS OF UP TO £277M (EUR 320M)
* GSK WILL FUND RESEARCH AND DEVELOPMENT ACTIVITIES AT CUREVAC RELATED TO DEVELOPMENT PROJECTS COVERED BY COLLABORATION
* WILL MAKE AN EQUITY INVESTMENT IN CUREVAC OF £130M (EUR 150M), REPRESENTING CLOSE TO A 10% STAKE Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.